Harvard Business Review

MARCH 2, 2012

In 2011, 71% of HBS's new cases were written about foreign companies. As a consequence, five of its CEOs have been non-American-born, including today's CEO, Turkish-born Muhtar Kent. Many global companies have followed Coke's lead by appointing foreign-born CEOs and executives.

Competitive Advantage 13

Competitive Advantage Globalization Development Intellectual Capital 13

In the CEO Afterlife

JUNE 19, 2011

In the CEO Afterlife. by John • June 19, 2011 • Life , Marketing , Strategy • 1 Comment. So do pharmaceutical giants Eli Lilly and Pfizer. June 21, 2011 at 5:57 pm. Formerlife: CEO of Jacobs Suchard (Nabob, Kraft), Strategy/Branding Consultant. December 2011. November 2011. August 2011.

Advice 147

Advice Marketing Marketing Strategy Brand 147

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. His friend, Dr. Shiping Liu, founder and CEO of Global Business Intelligence Consulting Co., Daniela Saltzman is an MBA student at HBS, class of 2011. Stay tuned. Eccles is a professor of management practice at HBS.

Long-term 15

Long-term Sample Report Pharmaceuticals 15

Harvard Business Review

OCTOBER 3, 2013

Take Citrus Lane CEO Mauria Finley, whose company was experiencing some growing pains, appropriately enough; the startup sends monthly packages of great baby products to moms. Back in 2011, in Citrus Lane’s first six months, its small founding team worked in a house and ate lunch together every day around a big table. After raising $5.1

Pharmaceuticals 8

Pharmaceuticals Seminar Learning-by-Doing Open-book 8

Harvard Business Review

SEPTEMBER 5, 2013

In 2011, Thierry Andretta, the CEO of French fashion company Lanvin, announced an initiative called "no email Wednesdays" because he thought people had stopped actually talking to each other. Marissa Mayer, Yahoo''s CEO, ended the company''s work-from-home policy to foster a more collaborative, innovative environment.

Productivity 8

Productivity Products Peer Review Short-term 8

Harvard Business Review

NOVEMBER 2, 2018

Workers’ increasing out-of-pocket costs are creating widespread discontent with the underlying costs of care — a problem largely driven by the high prices charged to private payers for health services and pharmaceuticals. Between 2011 and 2017, employees’ premiums and deductibles grew faster than their median income.

Health Care 8

Health Care Cost Insurance Price 8

Harvard Business Review

NOVEMBER 20, 2015

Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail. In 2011, Havens’ collaboration with IBM procurement paid off, winning Havens four significant projects.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

MAY 10, 2013

The next few product launches were not nearly as successful and Ed Zander , a CEO who came in during the successful period, was unable to come up with any more hits. Such a pattern is well established in the pharmaceutical industry as large established firms partner with smaller biotech firms.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

SEPTEMBER 11, 2014

Finally, industries in the upper-right quadrant — such as software, pharmaceuticals, and medical equipment — face high uncertainty in both demand and technology. Following the advice of then CEO Eric Schmidt to “get 100 happy users inside Google,” Bucheit prototyped solutions that eventually proved demand and won the day.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

DECEMBER 21, 2015

Which brings us back to Pfizer, the pharmaceutical drug company that has provoked the new round of patriotic denunciations of corporate tax flight. Pfizer’s CEO, Ian C. Since 2011, Read’s first full year as CEO, Pfizer has expended $44.2 billion on buybacks and $31.2

Hedge 8

Hedge Proposal Pharmaceuticals Price 8